Dong-A ST Co., Ltd. (KRX: 170900)

Market Cap	588.05B
Revenue (ttm)	675.41B
Net Income (ttm)	-6.68B
Shares Out	8.98M
EPS (ttm)	-1,101.35
PE Ratio	n/a
Forward PE	18.35
Dividend	686.27 (1.00%)
Ex-Dividend Date	n/a

Volume	14,341
Open	66,200
Previous Close	66,500
Day's Range	66,200 - 69,000
52-Week Range	53,725 - 88,000
Beta	0.67
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 1, 2024

About Dong-A ST

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Dulastin PFS and Leucostim injection/PFS to treat neutropenia in patients receiving myelosuppressive chemotherapy; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for infertility and anovulation...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Employees: 1,687
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 170900

Financial Performance

In 2023, Dong-A ST's revenue was 663.98 billion, an increase of 4.50% compared to the previous year's 635.39 billion. Earnings were 11.12 billion, a decrease of -17.93%.